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Abstract 40 
Livestock performance and feed efficiency are closely interrelated with the qualitative and 41 
quantitative microbial load of the animal gut, the morphological structure of the intestinal wall and 42 
the activity of the immune system. Antimicrobial growth promoters have made a tremendous 43 
contribution to the profitability in the intensive husbandry. As a consequence of the increasing 44 
concern about the potential for antibiotic resistant strains of bacteria, the European Commission 45 
decided to ban all commonly used feed antibiotics. There are a number of non-therapeutic 46 
alternatives, including enzymes, (in)organic acids, probiotics, prebiotics, etheric oils and 47 
immunostimulants. Their efficacy and mode of action is briefly described.  48 
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Introduction 60 
Antibiotics have been widely used in animal production for decades. Although some are 61 
used therapeutically to improve the health and well-being of animals, a large portion was employed 62 
for prophylactic purposes and to improve growth rate and feed conversion efficiency (as 63 
antimicrobial growth performance promoters, or AGPs). However, due to the emergence of 64 
microbes resistant to antibiotics which are used to treat human and animal infections, the European 65 
Commission (EC) decided to phase out, and ultimately ban (January 1st 2006), the marketing and 66 
use of antibiotics as growth promoters in feed (EC Regulation No 1831/20031). This political 67 
decision was taken by invoking the precautionary principle: ‘Where there are threats of serious or 68 
irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing 69 
cost-effective measures to prevent environmental degradation’ (Principle 15 of the Rio Declaration, 70 
19922
 72 
).  71 
In other countries, such as the USA, consumer pressure is pushing the poultry industry to 73 
rear animals without AGPs (Dibner and Richard, 2005; Castanon, 2007). AGP removal has led to 74 
animal performance problems, feed conversion increases, and a rise in the incidence of certain 75 
animal diseases, such as (subclinical) necrotic enteritis (Wierup, 2001; Dibner and Richards, 2005). 76 
One disease syndrome that is clearly emerging in the EU broiler industry simultaneously with the 77 
ban of growth promoting antibiotics is the so-called ‘dysbacteriosis’. This is a poorly described 78 
condition of the gut and may be synonymous with conditions such as ‘wet litter’, ‘small intestinal 79 
bacterial overgrowth’, ‘malabsorption’, ‘feed passage syndrome’ and others. The common clinical 80 
denominator is thinning and ballooning of the small intestine, increased water content of faeces and 81 
reduced digestibility of feed with indigested residues visible in the faeces.  82 
 83 
 
 
The impact of phasing out of animal growth promoters could be minimised provided that 84 
adequate attention is given to the implementation of alternative disease-prevention strategies and 85 
management factors, such as alternative husbandry practices in food animal production. Indeed, 86 
overall disease and performance problems have been rather limited, partly because ionophore 87 
anticoccidials are still available, therapeutic antibiotic use (e.g. macrolides and penicillins) has 88 
increased, and alternatives for AGPs have been empirically used such that those with the best 89 
effects on performance are currently used as feed additives.  90 
 91 
Characteristics of good AGP alternatives 92 
Ideally, alternatives to growth promoters should have the same beneficial effect as AGPs. It is 93 
however not totally clear how AGPs exert their beneficial action. The most well-known mechanism 94 
to be proposed is that AGPs have an antibacterial action that favours performance in different ways: 95 
(1) by reducing the incidence and severity of subclinical infections (George et al., 1982; Brennan et 96 
al., 2003); (2) by reducing the microbial use of nutrients (Snyder and Wostmann, 1987); (3) by 97 
improving absorption of nutrients because of thinning of the intestinal wall, and (4) by reducing the 98 
amount of growth-depressing metabolites produced by Gram-positive bacteria (Feighner and 99 
Dashkevicz, 1987; Knarreborg et al., 2004). The basis of this mechanistic explanation is that AGPs 100 
do not exert growth-promoting effects in germ-free animals (Coates et al., 1963).  101 
 102 
Although certain authors reason that AGPs are used in sub-therapeutic or sub-minimum 103 
inhibitor concentration (MIC) doses and so any growth-inhibitory action is unclear (Niewold, 104 
2007), clear shifts in the microbiota composition have been demonstrated when AGPs were added 105 
to broiler feed (Pedroso et al., 2006; Wise and Siragusa, 2007). Indeed, sub-MIC concentrations do 106 
                                                                                                                                                                                                
1 See: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:268:0029:0043:EN:PDF  
2 See: http://www.unep.org/Documents.Multilingual/Default.asp?DocumentID=78&ArticleID=1163  
 
 
not mean that growth-inhibition of certain bacterial species in the gut can be excluded but shifts in 107 
microbiota composition can, at least in theory, explain the effects of the AGPs. Furthermore, 108 
microbiota shifts can affect morphology of the gut wall and induce immune reactions that can have 109 
effects on energy expenses of the host (Humphrey and Klasing, 2003; Teirlynck et al., 2009).  110 
 111 
Niewold (2007) hypothesized that AGPs may be growth permitting by inhibiting the 112 
production and excretion of cytokines by immune cells (macrophages), after AGPs accumulate in 113 
these cells. Cytokine release would then lead to an acute phase response leading to loss of appetite 114 
and muscle tissue catabolism (Niewold, 2007). Certainly inflammation leads to performance 115 
decreases (Humphrey and Klasing, 2003), but equally AGPs may act by shifting the microbiota 116 
composition towards one that is less capable of evoking an inflammatory response. AGPs could 117 
also simply lower the total microbial load, leading to less inflammation and lower energetic cost for 118 
the animal. 119 
 120 
Whatever the mechanism of action of AGPs, the main characteristic of a good alternative from 121 
a practical point of view is that it must improve performance at least as well as AGPs. Based on the 122 
proposed mechanism of action of AGPs, both microbiota modulating and immunomodulatory 123 
compounds could have potential. There are many possible ways microbiota modulating compounds 124 
could influence the intestinal microbiota population without adding AGPs to the feed. The most 125 
obvious method is the use of therapeutic doses of antibiotics under prescription, a practice that will 126 
undoubtedly increase and (ironically) probably raise the likelihood of the emergence of resistant 127 
human pathogens.  128 
 129 
 
 
None of the non-antibiotic AGP alternatives suggested below is likely to compensate fully for 130 
the loss of AGPs. It must be emphasised that some strategies will only help to compensate partially 131 
(but will not replace) AGPs, and will work through indirect mechanisms. The list is by no means 132 
exhaustive and there are also other products claiming to be of value in AGP-free diets. 133 
 134 
Some alternatives for AGPs and their mode of action 135 
Exogenous enzymes  136 
Non-starch polysaccharides (NSPs) in animal feedstuffs are a complex group of components 137 
differing widely in chemical composition, physical properties and physiological activity, many of 138 
which have negative effects on growth and performance. NSPs include (hemi)celluloses, pectins 139 
and oligosaccharides as well as arabinoxylans and β-glucans (consisting of either a more soluble or 140 
a non-soluble fraction).  141 
 142 
Different cereal types contain variable NSP levels with concomitant differences in chemical 143 
composition. For example, maize contains almost exclusively insoluble NSPs, whereas wheat and 144 
barley contain NSPs of which the ratio of soluble to insoluble is about 1/6. This ratio is about 3/4 in 145 
rye, making this cereal one with particularly high levels of soluble NSPs (Choct, 2002).  146 
 147 
The mechanism by which NSPs exert their anti-nutritive effects is complex, but their viscous 148 
nature is considered a primary cause for their anti-nutritive effect in poultry. This is because the 149 
increased bulk and viscosity of the intestinal contents decrease the rate of diffusion of substrates 150 
and digestive enzymes and hinder their effective interaction at the mucosal surface (Choct et al., 151 
1996). NSPs also induce thickening of the mucous layer on the intestinal mucosa (Hedemann et al., 152 
 
 
2009) suggesting that the concentrations of soluble NSPs in wheat are inversely correlated with 153 
their metabolisable energy (MEn)-values in broiler chickens (Annison, 1991).  154 
 155 
In addition to the direct effect of viscous NSPs on gut physiology and morphology, there 156 
appear to be some indirect effects that could have important implications for the efficient use of 157 
nutrients by the chicken (Dänicke et al., 1999). One such indirect effect may be related to 158 
stimulation of fermentation of NSPs by the gut microbiota, leading to volatile fatty acid production 159 
(VFA) in the small intestine. Under normal circumstances with low NSP-diets, facultative 160 
anaerobes predominate in the chicken small intestine and nearly strict anaerobes make up the entire 161 
caecal microbiota (Salanitro et al., 1978; Lu et al., 2003; Bjerrum et al., 2006). On a NSP-rich diet, 162 
the VFA-concentration increases mainly in the distal ileal lumen due to excess fermentation 163 
combined with a proliferation of the fermentative microflora with a rather limited effect on the 164 
activity of the hindgut microbiota (Choct et al., 1996; 1999). Small intestinal fermentation indicates 165 
competition with the host for digestible nutrients. Enzyme-free diets containing soluble-NSP rich 166 
cereals (wheat) have been shown to induce lymphocyte infiltration in the gut wall and induce 167 
apoptosis of epithelial cells much more than cereals such as maize that have low levels of soluble-168 
NSPs (Teirlynck et al., 2009).  169 
 170 
Negative effects of diets with high NSP levels can be partly counterbalanced by adding AGPs 171 
(Teirlynck et al., 2009). Without these, supplementing the NSP-rich diet with enzymes results in 172 
both a reduction in ileal VFA-concentration and an elevation in caecal VFA-concentration (Choct et 173 
al., 1996) as more ‘low molecular weight’ fermentable material is entering the caecum. Caecal 174 
fermentation suggests the conversion of indigestible compounds into readily absorbable VFAs.  175 
 176 
 
 
Dietary NSP-enzymes work by reducing the viscosity of the digesta in the small intestine, so 177 
that digesta passage and nutrient digestion rate increase providing less substrate and less time for 178 
the fermentation organisms to proliferate. This may restore the normal and efficient endogenous 179 
enzymatic digestion of nutrients in the small intestine. The enzymes are partially counterbalancing 180 
the adverse effects of soluble NSP on performance (Bedford and Classen, 1992).  181 
 182 
It is not possible to measure the relative contribution following improved nutrient utilisation or 183 
the ‘selective’ reduction in the microbial population (Smits and Annison, 1996). However, there is 184 
evidence that the consequence of a NSP-mediated reduced rate of digestion is much more radical in 185 
the presence of intestinal microbiota due to the degradation of both digestive enzymes and bile salts 186 
and colonisation of the absorptive surface area (Smits and Annison, 1996). In the absence of 187 
antimicrobial growth promoters (as in the European Union), there will be a greater response to 188 
enzymes, particularly in less well-digested diets (Elwinger and Teglöf, 1991). Furthermore, NSP 189 
degrading enzymes will also reduce the proliferation of pathogenic bacteria such as Clostridium 190 
perfringens (Jackson et al., 2003). These days all broiler feed contains enzymes such as xylanases 191 
and beta-glucanases that breakdown NSPs.  192 
 193 
Organic acids 194 
Organic acids have been shown to have beneficial effects on performance. Some (e.g. butyric 195 
acid) also decrease the incidence of subclinical necrotic enteritis caused by C. perfringens, an 196 
additional beneficial effect which is highly relevant for the poultry industry (Timbermont et al., 197 
2009). Organic acids are widely distributed in nature as normal constituents of plants or animal 198 
tissues. They are also formed through microbial fermentation of carbohydrates predominantly in the 199 
caeca of poultry (Van Der Wielen et al., 2000).  200 
 
 
 201 
A wide range of organic acids with variable physical and chemical properties exists, of which 202 
many are used as drinking water supplements or as feed additives (acidifiers). Many are also 203 
available as sodium, potassium or calcium salts (and/or partially esterified). The advantage of salts 204 
over acids is that they are generally odourless and easier to handle in the feed manufacturing 205 
process owing to their solid and less volatile form. They are also less corrosive and may be more 206 
soluble in water.  207 
 208 
The mechanism of action of organic acids probably reflects their antibacterial nature, such as 209 
decreasing the pH of drinking water and reducing the buffering capacity of the feed with subsequent 210 
effect on the physiology of the crop and proventriculus (Thompson and Hinton, 1997; Van 211 
Immerseel et al., 2006). The ability of organic acids to change from undissociated to the dissociated 212 
form (depending on the environmental pH) enhances their antimicrobial effect. When the acid is in 213 
the undissociated form it can freely diffuse through the semi-permeable membrane of the 214 
microorganisms into the cell cytoplasm (Adams and Hall, 1988; Van Immerseel et al., 2006). Once 215 
in the cell, where the pH is maintained near 7, the acid will dissociate and suppress bacterial cell 216 
enzymes (e.g. decarboxylases and catalases) and nutrient transport systems. The efficacy of an acid 217 
in inhibiting microbes is dependent on its pKa value, which is the pH at which 50% of the acid is 218 
dissociated. Organic acids with higher pKa values are more effective antibacterial compounds and 219 
their efficacy is generally improved with increasing chain length and degree of unsaturation.   220 
 221 
In general, variables that influence antibacterial activity are (1) chemical formula, (2) pKa-222 
value of the acid, (3) chemical form (esterified or not, acid, salt, coated or not), (4) molecular 223 
weight, (5) the micro-organism related MIC-value of the acid, (6) the nature of the micro-organism, 224 
(7) animal species, and (8) the buffering capacity of the feed (Patten and Waldroup, 1988; 225 
 
 
Thompson and Hinton, 1997). It is thus clear that each acid has its own spectrum of microbial 226 
activity related to differences in both specific pH-range, membrane structure and in-cell physiology 227 
of the microbiota species.  228 
 229 
Blends of acids represent an array of pKa values and are used because of the broader spectrum 230 
of activity. The physical form of the acids also plays a role in the AGP replacement effect. The 231 
coating or micro-encapsulation of fatty acids with a progressive ‘slow release’ matrix is essential 232 
for their anti-microbial activity throughout the distal part of the gastro-intestinal tract. Also additive 233 
effects of acids are possible. There are indications that the medium chain fatty acids (with a chain 234 
length between 8 and 12 carbon atoms, e.g. caproic acid, has a lower absorption rate because of the 235 
higher molecular weight) may improve the efficacy of the short chain fatty acids. In the field, 236 
mixtures of organic acids are mainly used, which makes their spectrum broader and combines the 237 
good qualities of the different acids.  238 
 239 
The possibility that providing additional organic acids in the feed may act as a rapidly 240 
absorbed energy source cannot yet be ruled out. Moreover, there is some evidence of increased 241 
growth of the gastro-intestinal mucosa in the presence of organic acids, particularly fatty acids such 242 
as butyric acid. It has been well documented that butyric acid exerts a wide variety of effects on 243 
intestinal function in rodents and humans, and these effects may also be present in livestock. 244 
Indeed, butyric acid has been shown to be an important energy source for gut epithelial cells and to 245 
stimulate epithelial cell proliferation and differentiation (Dalmasso et al., 2008). Butyric acid also 246 
has well documented anti-inflammatory effects (Hodin, 2000) and has been shown to strengthen the 247 
gut mucosal barrier by increasing production of antimicrobial peptides in mucous and by 248 
stimulating the expression of tight junction proteins (Mariadason et al., 1997; Schauber et al., 2003; 249 
Bordin et al., 2004; Peng et al., 2007). Thus for some acids, especially butyric acid, not only 250 
 
 
antibacterial but also host effects can play a role in the AGP-replacement effect. Whether other 251 
acids, such as medium-chain fatty acids, have similar effects on host cell activities has not yet been 252 
investigated. 253 
 254 
Probiotics or ‘direct-fed microbials’ 255 
Probiotics have been defined as 'mono- or mixed cultures of living microorganisms which 256 
beneficially affect the host by improving the properties of the indigenous microbiota’ (Fuller, 1992). 257 
The available probiotics can be classified into (1) ‘colonizing’ species, such as Lactobacillus and 258 
Enterococcus spp., and (2) free flowing ‘non-colonizing’ species, such as Bacillus spp. (spores) and 259 
Saccharomyces cerevisiae. Competitive exclusion (CE) describes the treatment of day-old chicks 260 
with an undefined microbiota derived from adult animals resulting in colonisation resistance against 261 
pathogenic microorganisms.  262 
 263 
There is considerable variation in published studies that evaluate the effect of probiotic strains 264 
on performance. It is not the aim of the current review to summarise these data but the search terms 265 
PROBIOTICS, PERFORMANCE and POULTRY in Medline leads to numerous publications on 266 
this issue. The differences in outcome are most likely due to differences in dose and nature of the 267 
administered strains and their persistence (relative intestinal concentration), stability during feed 268 
manufacturing (as well as in the gastro-intestinal tract), variation in the physiological state of the 269 
bird, and the actual microbiota balance in the gut of the animal. The ideal probiotic should be an 270 
image of the indigenous strains resistant to feed processing (a coating might be helpful, e.g. for 271 
living yeast cells), as well as acidity, and the effects of bile salts and digestive enzymes. It must also 272 
be rapidly proliferating. Bacteria intended for probiotic use should be screened for antibiotic 273 
resistance to avoid any potential carriage of undesirable antibiotic resistance into the intestinal 274 
environment.  275 
 
 
 276 
The mechanism of action of probiotics as AGP replacers will depend on the nature of the 277 
organism and is not always clear. The different bacterial species in the normal microbiota 278 
(colonising on the epithelium of the digestive tract or occurring freely in the gut lumen) of the 279 
broiler gut reach a typical equilibrium state after about a week post-hatch, and depends on many 280 
factors including location in the gastro-intestinal tract, integrity of the intestinal mucosa and transit 281 
time of the chymus (Van Der Wielen et al., 2000; 2002; Teirlynck et al., 2009).  282 
 283 
The intestinal microbiota has a specific multifactorial 'barrier' impact, such as (1) induction of 284 
anatomical and physiological changes in the intestinal cell wall structure, (2) immunological 285 
modifications in the gut, and (3) enhancement of the bird’s resistance to enteropathogenic bacteria, 286 
such as C. perfringens (Nurmi and Rantala, 1973; Hofacre et al., 1998; La Ragione et al., 2004; 287 
Kalliomaki et al., 2008; Ng et al., 2009). Depending on the probiotic strain, the mode of action 288 
probably involves production of specific metabolites (short organic fatty acids, H2O2, intermediary 289 
metabolites with antimicrobial activity), interaction with receptor sites, stimulation of the immune 290 
system and some others (Madsen, 2001; Sherman et al., 2009).  291 
 292 
The most well known group of probiotics are lactic acid bacteria. It has been shown that lactic 293 
acid produced in vitro by lactic acid bacteria is used by the strictly anaerobic butyrate producing 294 
bacteria of Clostridial clusters IV and XIVa for the production of large concentrations of butyric 295 
acid (Duncan et al., 2004). This mechanism is called cross-feeding and is a further reason why 296 
lactic acid bacteria administration can beneficially affect performance (see above in the section on 297 
butyric acid).  298 
 299 
 
 
Prebiotics 300 
Prebiotics can be defined as non-digestible feed ingredients with selective effects on the 301 
intestinal microbiota. Oligosaccharides are the main components and the range is diverse and may 302 
be based on any of the hexose monosaccharides, including glucose, fructose, galactose and mannose 303 
(Durst, 1996) with a polymerisation degree of between 2 and 20 monosaccharides. Grain legumes 304 
are the most common natural sources of oligosaccharides, being present as raffinose, stachyose and 305 
verbascose. 'Synthetic' oligosaccharides are derived from the direct polymerisation of disaccharides 306 
or from the fractionation of both vegetable and microbial cells. Oligosaccharides such as 307 
arabinogalactose, arabinoxylan and rhamnogalacturonose are derived from polysaccharides of 308 
soybean (with about 3-5% galacto-oligosaccharides), wheat and fruit, respectively (Schols et al., 309 
1994; Huisman et al., 2001; Van Craeyveld et al., 2009).. 310 
 311 
The mechanism of action of prebiotics as AGP replacers is dependent on the nature of the 312 
compound. They are non-digestible feed ingredients that can have a beneficial action because of 313 
selective stimulation of the growth or metabolic activity of a limited number of intestinal microbiota 314 
species, such as Bifidobacteria and Lactobacillus spp. (Gibson and Roberfroid, 1995). Thus they 315 
may have a similar mechanism of action as probiotics.  316 
 317 
Conflicting results obtained with or without oligosaccharides that occur naturally in feed 318 
ingredients (for example the raffinose series oligosaccharides) present an unclear scenario regarding 319 
the effect of their inclusion in diets for broilers (Coon et al., 1990; Leske et al., 1991; Iji and Tivey, 320 
1998); however, their nutritional impact cannot be separated from other anti-nutritive components 321 
in the diet. The lack of any beneficial effect might be related to the non-specificity of the process of 322 
hindgut fermentation. When ingested, prebiotics stimulate the growth and/or metabolic activity of 323 
 
 
different bacterial species, including species that are both potentially harmful and beneficial 324 
(Maczulak et al., 1993).  325 
 326 
Results obtained from synthetic materials suggest some benefits using inulin and fructo-327 
oligosaccharides (FOS) that act as substrates for ‘desired’ microorganisms, for example 328 
bifidobacteria (Waldroup et al., 1993; Iji and Tivey, 1998; Verdonk et al., 2005; Ramirez-Farias et 329 
al., 2009), whereas manno-oligosaccharides (MOS) have receptor properties for fimbriae of E. coli 330 
(sensitive to mannose) and Salmonella spp., which leads to elimination of these bacteria with the 331 
digesta flow instead of binding a mucosal receptor (Ofek et al., 1977; Spring et al., 2000; Parks et 332 
al., 2001; Fernandez et al., 2002).  333 
 334 
Oligosaccharide beta-glucans of yeast cell wall origin are thought to stimulate performance 335 
because of their immunomodulatory effects. Their main action is to enhance phagocytosis and 336 
proliferation of monocytes and macrophages (Novak and Vetvicka, 2009). As macrophages play a 337 
crucial role in immunomodulation, the interaction of glucans with macrophages can have huge 338 
effects in the host. Recent reviews elaborate on the action of glucans on immune stimulation 339 
(Schepetkin and Quinn, 2006; Novak and Vetvicka, 2009). Studies with animals have documented 340 
significant health benefits from using immune modulating β-1,3/1,6-glucan (from yeast cell walls) 341 
as a feed ingredient to protect animals against micro-organisms (Williams et al., 1996).  342 
 343 
One approach for future research will be to examine the combination of both probiotics and 344 
prebiotics (as 'synbiotics'), which may be defined as a mixture of probiotics and prebiotics that 345 
beneficially affects the host by improving the survival and persistence of living microbial dietary 346 
supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating 347 
 
 
the metabolism of one or a limited number of health-promoting bacteria (Patterson and Burkholder, 348 
2003). This combination would thus combine substrate and bacteria. 349 
 350 
Herbs and etheric oils  351 
Many plants have beneficial multifunctional properties derived from their specific bio-active 352 
components. Biologically active constituents of plants are mostly secondary metabolites, such as 353 
terpenoids (mono-and sesquiterpenes, steroids, etc.), phenolics (tannins), glycosides and alkaloids 354 
(present as alcohols, aldehydes, ketones, esters, ethers, lactones, etc.). There is a lot of variation in 355 
composition due to biological factors (plant species, growing location, and harvest conditions), 356 
manufacturing (extraction/distillation, stabilization) and storage conditions (light, temperature, 357 
oxygen tension and time). The challenge is to identify and quantify the multitude of actions and 358 
claims improving feed utilisation, animal physiology and health status.  359 
 360 
Because of possible ‘synergy’ between constituents, it remains unclear which components of 361 
etheric oil products may stimulate the endogenous digestive enzymes, act as an antioxidant, 362 
antimicrobial agent, or immunomodulator. There are experimental data showing the in vitro anti-363 
microbial effects with respective MIC-values and spectrum of activity (see, for example, Penalver 364 
et al., 2005; Fu et al., 2007; Barbosa et al., 2009). According to Adams (1999) the antimicrobial 365 
activity is rather weak for ginger and pepper, medium for cumin (p-cymene), coriander (lialol), 366 
oregano (carvacrol), rosemary (cineol), sage (cineol) and thyme (thymol) and strong for clove 367 
(eugenol), mustard (allylisothiocyanate), cinnamon (cinnamaldehyde) and garlic (allicin).  368 
 369 
Regulations concerning feed additives for animal use 370 
 
 
A zootechnical additive is any additive other than feed material and pre-mixtures used to 371 
affect favourably the performance of animals in good health or used to affect favourably the 372 
environment. The category ‘zootechnical additive’ can be further divided into four functional 373 
groups: (1) digestibility enhancers; these are substances which, when fed to animals, increase the 374 
digestibility of the diet, through action on target feed materials; (2) gut flora stabilisers; these are 375 
micro-organisms or other chemically defined substances, which, when fed to animals, have a 376 
positive effect on the gut flora; (3) substances which favourably affect the environment; (4) other 377 
zootechnical additives. 378 
 379 
EC Regulation 1831/2003 will establish a Community procedure for authorising the placing 380 
on the market and use of feed additives and to lay down rules for the supervision and labelling of 381 
feed additives and pre-mixtures in order to provide the basis for the assurance of a high level of 382 
protection of human health, animal health and welfare, environment and users' and consumers' 383 
interests in relation to feed additives, whilst ensuring the effective functioning of the internal 384 
market. This Regulation will not apply to processing aids and veterinary medicinal products as 385 
defined in Directive 2001/82/EC3, with the exception of coccidiostats and histomonostats used as 386 
feed additives. However, prebiotics (inulin, fructo-mannanoligosaccharides, yeast cell walls rich in 387 
beta-glucans) or short and medium chain fatty acids are considered as feedstuffs and not as feed 388 
additives and so fall under the scope of Regulation 0767/20094
 392 
 concerning the trade of animal 389 
feeds. However, the classification of a product as either a feedstuff or a feed additive remains 390 
unclear because of differences in the relative impact of technological processing. 391 
Botanical or herbal extracts, flavours and etheric oils (EOs) now fall within the scope of EC 393 
Regulation 1831/2003. In general, unprocessed herbs are regarded as feed materials and do not need 394 
                                                          
3 See: http://www.echamp.eu/fileadmin/user_upload/Regulation/Directive_2001-82-EC__-
__Consolidated_Version_.pdf  
4 See: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:229:0001:0028:EN:PDF  
 
 
authorisation. Notified plant extracts or components are included in the Community Register of 395 
Feed Additives5. This register has only informative purposes and does not replace Community legal 396 
acts. The Community legal acts concerning the authorisation of each additive entered in the 397 
Register constitute the legal basis for the placing on the market and use of additive concerned. This 398 
means that before November 2010, a complete scientific dossier for each notified EO or component 399 
shall be submitted to EFSA (European Food Safety Authority) which provides guidance on 400 
scientific data needed to carry out a safety assessment for botanical agents6. After a full evaluation 401 
by EFSA, a positive outcome and authorisation by the Standing Committee on the Food Chain and 402 
Animal Health (SCFCAH), these EOs can be used legally in the EU in animal nutrition7. The actual 403 
status of the EFSA evaluation of the scientific dossier can be checked at the Register of Questions8
 405 
. 404 
Economical considerations 406 
The general health status determining the performance of broilers is multifactorial. Good 407 
management relies on continuous monitoring of the flock for health status and performance. 408 
Monitoring of the health status requires regular necropsies with determinations of lesion scores, and 409 
identification of pathogens including the make-up of an antibiogram. Monitoring of performance 410 
requires information such as feed intake and weight gain, flock uniformity, litter score, climatic and 411 
other conditions. This should, at least in theory, provide a view of the cost of the ban in terms of 412 
decreased growth rate, higher morbidity and mortality, increased condemnations, and depressed 413 
yield.  414 
 415 
The return-on-investment for alternatives to AGPs will depend on both the biological impact 416 
and the actual market price. It must take into account the fact that the feed cost of these alternatives 417 
                                                          
5 See: http://ec.europa.eu/food/food/animalnutrition/feedadditives/registeradditives_en.htm 
6 http://www.efsa.europa.eu/cs/BlobServer/Guidance_of_Panel/sc_op_ej1249_botanicals_en.pdf 
7 http://ec.europa.eu/food/food/animalnutrition/feedadditives/index_en.htm 
8 http://registerofquestions.efsa.europa.eu/roqFrontend/questionsList.jsf 
 
 
is quite variable, ranging from (€/ton9
 424 
): 2-3 for enzymes, 3-12 for organic acids, 4-7 for probiotics, 418 
9-17 for immunostimulants, 2-15 for oligosaccharides, 3-25 for herbs and etheric oils (in 419 
comparison with 1-2 and 2-4 for respectively feed antibiotics and anticoccidials, depending on dose 420 
and type of product). The net economic effect will depend on several factors including the effects 421 
on performance levels and the cost of any technologies adopted to compensate for the termination 422 
of AGPs, and may be offset by the benefits of increased consumer confidence.  423 
Unlike with pigs, termination of AGPs in European poultry has not resulted in increases in 425 
therapeutic use of antimicrobials largely because of the continuing use of ionophores for the 426 
prophylaxis of coccidiosis (Grave et al., 2006). Indeed both chemical and ionophore anticoccidials 427 
are almost universally used in the broiler industry. Without these drugs (e.g. during the withdrawal 428 
period), birds will become infested and damage to the intestinal epithelial cells will provide further 429 
opportunities for ‘subclinical’ necrotic enteritis and performance problems. Ionophore 430 
anticoccidials also have an additional antibacterial potential. In article 11 of the European Council 431 
regulation 1831/2003, the European Union states that the use of anticoccidials as feed additives 432 
should be phased out by December 2012. However, in 2008, the European Commission submitted a 433 
report on the use of these substances as feed additives and existing alternatives to the Council and 434 
the European Parliament (COM/2008/023310
 439 
). In this report, the European Commission clearly 435 
recommends maintaining the current legislation and allowing the use of ionophore anticoccidials as 436 
feed additives because of the lack of alternatives and to preserve the economic viability of the 437 
poultry industry.  438 
AGP replacers seem to be adequate when other control measures that beneficially affect gut 440 
health are also applied. The question remains whether the current AGP replacers have enough 441 
                                                          
9 €1 = approx. £0.89 , $1.43, as at 07 January 2010. 
 
 
potential to replace both AGPs and anticoccidials. There is a need to set and then to meet standards 442 
for the replacement of antibiotic compounds in poultry, in terms of product type, identification of 443 
suppliers, poultry response criteria, regulatory status and veterinary definition (Rosen, 2003).  444 
 445 
Conclusions 446 
Alternatives for AGPs are only of practical significance when they improve animal performance at 447 
levels comparable to AGPs.  Microbiota modulating and immunomodulatory compounds have 448 
potential and are used as feedstuff of feed additives. Enzymes, acids, per- and probiotics and herbs 449 
or etheric oils are some examples of product classes which are used as alternatives for AGPs. 450 
Within each product class, numerous products are on the market, and while some products clearly 451 
have potential, for others the efficacy is not clear. There is thus an urgent need to describe the 452 
mechanism of action of these compounds in a scientific way and to set and meet standards for AGP 453 
alternatives for broilers. 454 
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